Genomics

This is the latest episode of the free narrated DDW podcast, “Is genomic data the new frontier in drug discovery?” It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Genomics boosts understanding of Covid-19 severity and susceptibility” and “Rare variant contribution to human disease”. The Covid-19 […]

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for […]

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for […]

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for […]

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for the […]

By Lu Rahman  There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research reports that the global market for […]

Verge Genomics, a clinical-stage, tech-enabled biotechnology company using artificial intelligence (AI) and human data to transform drug discovery, has announced today that the first subject has been dosed in a Phase I clinical trial of VRG50635 for amyotrophic lateral sclerosis (ALS).  VRG50635 is a small molecule inhibitor of PIKfyve, a novel therapeutic target for ALS […]

A new laboratory specialising in genomics is set to open at the North Carolina Research Campus (NCRC) in Kannapolis, North Carolina. The Bill and Shari Graham Genomics Laboratory is a collaborative project from Catawba College and Eremid Genomic Services. The Lab will offer the only undergraduate next-generation DNA sequencing (NGS) training in the United States. […]

Oncology platform company Tavros Therapeutics and biopharmaceutical company Vividion Therapeutics (a subsidiary of Bayer AG) have agreed to collaborate on four oncology targets across an initial five-year term. Tavros’ functional and computational genomics technologies are designed to uncover unique vulnerabilities within tumours to discover novel targets and biomarkers in areas of high unmet clinical need. […]

Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time.  Precision medicine promises a paradigm shift to confidently match the right patients to the right treatment at the right time. In pursuit of this, the […]